VILON - Research Grade Peptide

VILON – Research-Grade Lys-Glu Dipeptide

For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, consumption, clinical use or therapeutic application. It must not be used in any way that contravenes applicable laws or the requirements of the Medicines and Healthcare products Regulatory Agency.

• Research-grade, sequence-defined L-lysyl-L-glutamic acid dipeptide
• Defined H-Lys-Glu-OH structure comprising two L-amino-acid residues
• Batch documentation available where supplied for the applicable production lot
• Supplied as measured dry or lyophilised laboratory material in sealed flip-top headspace vials
• Batch identity, chromatographic purity, molecular mass, dipeptide content and analytical specifications stated in the applicable Certificate of Analysis
• Handled and supplied exclusively as a research-use laboratory material

Vilon is a short synthetic dipeptide comprising L-lysine followed by L-glutamic acid. It is also identified as L-lysyl-L-glutamic acid, Lys-Glu, the KE dipeptide and H-Lys-Glu-OH. Each vial contains measured laboratory material prepared to support controlled scientific handling, storage, analytical method development and dipeptide characterisation.

The stated nominal amount refers to the declared Vilon or L-lysyl-L-glutamic acid content of a single vial, subject to the applicable batch documentation and stated assay basis. Total vial mass may additionally include residual water, counter-ions or declared formulation components, which should be identified separately in the applicable Certificate of Analysis.

Where laboratory dissolution is required, the solvent, buffer, concentration, mixing procedure and storage conditions stated in the applicable Certificate of Analysis, Safety Data Sheet or validated laboratory method should be followed. A universal bacteriostatic-water instruction should not be applied to every Vilon chemical form or laboratory preparation. We do not provide advice or recommendations concerning dosage, administration or use in humans or animals.

Chemical and Structural Information:

• Product Name: VILON
• Preferred Chemical Name: L-Lysyl-L-glutamic acid
• Alternative Names: Vilon; Lysylglutamic acid; Lys-Glu; L-Lys-L-Glu; Lysylglutamate; KE dipeptide; H-Lys-Glu-OH; N-L-lysyl-L-glutamic acid
• Qualified Catalogue Alias: Normophthal appears in some substance and catalogue synonym lists, but product identity should not be assigned solely from this trade name
• Material Classification: Synthetic sequence-defined linear dipeptide
• Sequence Length: Two amino-acid residues
• Complete Peptide Sequence: H-L-Lys-L-Glu-OH
• Three-Letter Sequence: Lys-Glu
• One-Letter Sequence: KE
• IUPAC Name: (2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]pentanedioic acid
• Peptide-Bond Structure: Standard alpha-peptide bond connecting the alpha-carboxyl group of L-lysine to the alpha-amino group of L-glutamic acid
• N-Terminal Structure: Free L-lysine alpha-amino terminus
• Lysine Side-Chain Structure: Free epsilon-amino group
• C-Terminal Structure: Free L-glutamic acid alpha-carboxylic acid terminus
• Additional Acidic Group: Free L-glutamic acid side-chain carboxylic acid
• Cyclic or Linear Structure: Linear dipeptide
• Cysteine Content: None
• Disulphide-Bond Content: None
• Sulphur Content: None
• CAS Number: 45234-02-4
• PubChem Compound Identifier: CID 7010502
• Unique Ingredient Identifier: H34V7IM5ML
• Molecular Formula: C₁₁H₂₁N₃O₅
• Average Molecular Weight: Approximately 275.30 g/mol
• Monoisotopic Mass: Approximately 275.1481 Da
• InChIKey: UGTZHPSKYRIGRJ-YUMQZZPRSA-N
• Formula Basis: The molecular formula and molecular weight describe the uncountered L-Lys-L-Glu free-acid molecule without additional acetate, trifluoroacetate, sodium, residual water, solvent or formulation components
• Physical Form: Dry powder or lyophilised laboratory material, as stated in the applicable batch Certificate of Analysis
• Appearance: White to off-white laboratory material, subject to confirmation in the applicable batch Certificate of Analysis
• Purity Specification: The applicable chromatographic purity result, analytical method and acceptance criterion should be stated in the batch Certificate of Analysis
• Purity Interpretation: Chromatographic purity represents the relative chromatographic composition measured under the stated analytical conditions and should not automatically be interpreted as equivalent to total net Vilon content
• Dipeptide-Content Specification: Net L-Lys-L-Glu content should be distinguished from chromatographic purity and interpreted alongside counter-ion content, water content, residual solvents and formulation components
• Nominal Amount Basis: The applicable product specification should state whether the declared vial quantity is expressed as anhydrous Vilon equivalent or as total supplied salt-form or formulated lyophilised material
• Sequence Confirmation: The Lys-Glu sequence should be confirmed using the applicable supplier, synthesis and batch records
• Sequence-Direction Confirmation: L-Lys-L-Glu should be distinguished from the sequence-reversed L-Glu-L-Lys dipeptide
• Stereochemical Confirmation: The L configuration of both the lysine and glutamic acid residues should be supported by suitable synthesis records or analytical documentation
• Free-Amino-Acid Distinction: A physical mixture of free L-lysine and L-glutamic acid is not chemically identical to the covalently linked Lys-Glu dipeptide
• Mass-Spectrometry Confirmation: Molecular identity should be supported by analytical mass data consistent with the specified L-lysyl-L-glutamic acid structure
• Chemical-Form Confirmation: The applicable Certificate of Analysis should identify whether the supplied material is the uncountered parent dipeptide, a sodium-containing form, an acetate-containing form, a trifluoroacetate-containing form or another salt presentation
• Counter-Ion Specification: Sodium, acetate, trifluoroacetate or another counter-ion may affect the total supplied material mass, formula weight and calculated net Vilon content
• Water-Content Specification: Residual water and hydration state may contribute to the total material mass and should be stated or controlled through the applicable batch specification
• Residual-Solvent Specification: Applicable residual solvents arising from synthesis, cleavage, purification, concentration and lyophilisation should be stated or controlled through the batch specification
• Related-Impurity Control: Free lysine, free glutamic acid, sequence-reversed Glu-Lys, incomplete coupling products, stereochemical impurities and other synthesis-related or process-related substances are separate quality attributes
• Dissolution Method: The appropriate solvent, buffer, concentration and mixing procedure should be selected using the applicable batch documentation and validated laboratory method; a universal bacteriostatic-water instruction should not be applied to every Vilon preparation
• Endotoxin Specification: The applicable bacterial endotoxin or lipopolysaccharide result, analytical method, reporting units, method-suitability controls and acceptance criterion should be stated in the batch Certificate of Analysis
• Sterility Distinction: A bacterial endotoxin or lipopolysaccharide result does not establish sterility. Sterility should only be claimed where supported by an appropriate validated sterility test and controlled filling process
• Analytical Interpretation: Molecular identity, sequence direction, stereochemistry, chromatographic purity, net dipeptide content, salt form, water content, residual solvents and bacterial endotoxin results are separate analytical measurements and should be interpreted together

✓ Batch documentation – Completed Certificate of Analysis documentation is provided where supplied for the applicable batch.
✓ Certificate of Analysis – Accessible through the product QR code where a completed batch-specific document has been published.
✓ Safety Data Sheet – Supplied to support appropriate laboratory handling, storage and regulatory compliance.
✓ Sequence documentation – The defined H-Lys-Glu-OH structure should be confirmed using the applicable synthesis and batch records.
✓ Stereochemical documentation – The L configuration of both amino-acid residues should be supported by appropriate synthesis or analytical records.
✓ Sequence-direction documentation – Lys-Glu should be distinguished from Glu-Lys and from a physical mixture of the two free amino acids.
✓ Mass-spectrometry documentation – Molecular identity should be supported by analytical mass data consistent with the specified Vilon structure.
✓ Purity documentation – The reported chromatographic purity applies only to the analytical method and batch stated in the Certificate of Analysis.
✓ Dipeptide-content documentation – Net Vilon content should be distinguished from chromatographic purity and interpreted alongside water, counter-ion and residual-solvent results.
✓ Chemical-form documentation – The parent dipeptide, sodium-containing, acetate-containing, trifluoroacetate-containing or another salt form should be identified clearly.
✓ Related-substance documentation – Free amino acids, incomplete coupling products, sequence-reversed material and stereochemical impurities should be controlled as applicable.
✓ Bacterial endotoxin documentation – The applicable bacterial endotoxin or lipopolysaccharide result should identify the analytical method, reporting units, method-suitability controls and acceptance criterion.
✓ Supplier documentation – Reviewed where supporting synthesis, purification and analytical records are supplied.
✓ Trackable laboratory delivery – Securely packaged and dispatched using transport controls appropriate to the applicable batch stability and storage specification.

For Research Use Only
This product is supplied strictly for scientific research, laboratory analysis and experimental work. It is not intended for human consumption, animal use, clinical use, diagnostic use or any form of therapeutic application.

Vilon Product Overview

Our research-grade Vilon Lys-Glu dipeptide is supplied for controlled analytical method development, short-peptide identity assessment, high-performance liquid chromatography evaluation, liquid chromatography–mass spectrometry workflows, impurity profiling, reference-material comparison and other scientific laboratory investigations.

Vilon comprises two covalently linked L-amino-acid residues in the defined sequence L-lysine followed by L-glutamic acid. The sequence may be written as Lys-Glu, KE or H-Lys-Glu-OH. The intact dipeptide should be distinguished from the individual free amino acids and from the sequence-reversed Glu-Lys molecule.

The CAS number 45234-02-4, molecular formula C₁₁H₂₁N₃O₅ and average molecular weight of approximately 275.30 g/mol describe the uncountered L-lysyl-L-glutamic acid molecule. Where the supplied laboratory material contains sodium, acetate, trifluoroacetate, residual water, solvents or formulation ingredients, the applicable batch documentation should identify their contribution to the total supplied material mass.

The material is handled with a focus on batch traceability, documented quality control and consistent laboratory presentation. Product identity, sequence direction, stereochemical configuration, chromatographic purity, net dipeptide content, molecular form, counter-ion content, water content, residual solvents, bacterial endotoxin results and other analytical specifications should be confirmed using the applicable batch Certificate of Analysis.

Chromatographic purity should not automatically be interpreted as equivalent to total net Vilon content or proof of correct sequence direction and stereochemistry. Molecular identity should be assessed using the applicable combination of chromatographic, mass-spectrometry, dipeptide-content and batch-manufacturing documentation.

A bacterial endotoxin or lipopolysaccharide result does not establish sterility, complete molecular identity, sequence direction, stereochemical integrity or the absence of every dipeptide-related and process-related impurity. Any sterility claim must be supported separately by an appropriate validated sterility test and controlled production documentation.

For the majority of routine analytical method development, chromatographic assessment, mass-spectrometry comparison, impurity profiling, reference-material evaluation and general laboratory work, the Regular Vilon specification remains highly suitable. The premium black-and-gold ULTIMATE Vilon option provides an additional preparative high-performance liquid chromatography purification stage and a more stringent bacterial endotoxin or lipopolysaccharide testing specification for projects requiring enhanced quality-control parameters.

View Certificate of Analysis

View Safety Data Sheet